Senior insider sale
CHIEF SCIENTIFIC OFFICER at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$7.05M
257.50K shares
LYSSIKATOS JOSEPH P plans to sell 257.50K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $7.05M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Founder Shares
N/A
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
9/1/2019 | Founder Shares N/A | 25K | — |
| Total | 25K | ||
Completed
Units to sell
5K
Market value
$144.6K
Units to sell
20K
Market value
$520.2K
Units to sell
50K
Market value
$1.32M
Units to sell
5K
Market value
$145.2K
Units to sell
20K
Market value
$535.1K
Units to sell
91.20K
Market value
$2.48M
Units to sell
41.30K
Market value
$993.4K
Planned — Approximate Date
Units to sell
25K
Market value
$914.8K
Units
257.50K
Value
$7.05M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
2/25/2026 | 5K | $144.6K | — | Completed |
2/19/2026 | 20K | $520.2K | — | Completed |
2/18/2026 | 50K | $1.32M | — | Completed |
2/6/2026 | 5K | $145.2K | — | Completed |
1/20/2026 | 20K | $535.1K | — | Completed |
1/9/2026 | 91.20K | $2.48M | — | Completed |
1/8/2026 | 41.30K | $993.4K | — | Completed |
| Planned — Approximate Date | ||||
3/31/2026 | 25K | $914.8K | Nasdaq | Planned |
| Total | 257.50K | $7.05M | ||